In TDP-43 proteinopathies, it has been shown that drugs increasing endogenous parkin levels were also able to decrease nuclear TDP-43 levels and prevent the neuronal loss and cognitive and motor decline in transgenic mice expressing either wild-type human TDP-43 or mutant A315T [97,183,184]. The gene discussed is TARDBP; the disease is proteostasis deficiencies.